CA3138240C - CRYSTALLINE FORMS OF A WEE1 INHIBITING COMPOUND AND RELATED USES - Google Patents
CRYSTALLINE FORMS OF A WEE1 INHIBITING COMPOUND AND RELATED USESInfo
- Publication number
- CA3138240C CA3138240C CA3138240A CA3138240A CA3138240C CA 3138240 C CA3138240 C CA 3138240C CA 3138240 A CA3138240 A CA 3138240A CA 3138240 A CA3138240 A CA 3138240A CA 3138240 C CA3138240 C CA 3138240C
- Authority
- CA
- Canada
- Prior art keywords
- crystal form
- pattern
- compound
- formula
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910364694 | 2019-04-30 | ||
| CN201910364694.X | 2019-04-30 | ||
| PCT/CN2020/088451 WO2020221358A1 (zh) | 2019-04-30 | 2020-04-30 | Wee1抑制剂化合物的晶型及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3138240A1 CA3138240A1 (en) | 2020-11-05 |
| CA3138240C true CA3138240C (en) | 2025-04-01 |
Family
ID=73029676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3138240A Active CA3138240C (en) | 2019-04-30 | 2020-04-30 | CRYSTALLINE FORMS OF A WEE1 INHIBITING COMPOUND AND RELATED USES |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12291536B2 (https=) |
| EP (1) | EP3964510B1 (https=) |
| JP (1) | JP7582970B2 (https=) |
| CN (1) | CN113784968B (https=) |
| AU (1) | AU2020266956B2 (https=) |
| BR (1) | BR112021021230A8 (https=) |
| CA (1) | CA3138240C (https=) |
| DK (1) | DK3964510T3 (https=) |
| ES (1) | ES2984617T3 (https=) |
| FI (1) | FI3964510T3 (https=) |
| HR (1) | HRP20241008T1 (https=) |
| HU (1) | HUE068061T2 (https=) |
| IL (1) | IL287472A (https=) |
| LT (1) | LT3964510T (https=) |
| PL (1) | PL3964510T3 (https=) |
| PT (1) | PT3964510T (https=) |
| RS (1) | RS65747B1 (https=) |
| SG (1) | SG11202111315XA (https=) |
| SI (1) | SI3964510T1 (https=) |
| SM (1) | SMT202400303T1 (https=) |
| WO (1) | WO2020221358A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| PE20080695A1 (es) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| CA2667345C (en) * | 2006-10-27 | 2016-03-22 | Signal Pharmaceuticals, Llc | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith |
| JP5411847B2 (ja) * | 2007-04-25 | 2014-02-12 | Ｍｓｄ株式会社 | Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 |
| WO2009054332A1 (ja) | 2007-10-23 | 2009-04-30 | Banyu Pharmaceutical Co., Ltd. | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
| EP2477628B1 (en) | 2009-09-15 | 2014-08-20 | Merck Sharp & Dohme Corp. | Preparation of crystalline hemihydrate forms of dihydropyrazolopyrimidinone |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| WO2013012681A1 (en) | 2011-07-15 | 2013-01-24 | Abbott Laboratories | Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
| US8796289B2 (en) | 2011-07-19 | 2014-08-05 | Abbvie Inc. | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases |
| US9181239B2 (en) | 2011-10-20 | 2015-11-10 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| MX2014010176A (es) | 2012-02-23 | 2014-11-10 | Abbvie Inc | Inhibidores de cinasas de piridopirimidinona. |
| GB201306610D0 (en) | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| WO2015019037A1 (en) | 2013-08-05 | 2015-02-12 | Almac Discovery Limited | Pharmaceutical compounds |
| GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| JP6692423B2 (ja) | 2015-11-01 | 2020-05-13 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト | Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法 |
| US11248006B2 (en) | 2017-03-23 | 2022-02-15 | Shanghai De Novo Pharmatech Co., Ltd. | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof |
| SG11202003974XA (en) * | 2017-11-01 | 2020-05-28 | Shijiazhuang Sagacity New Drug Development Co Ltd | Macrocyclic compound serving as weel inhibitor and applications thereof |
| US12180184B2 (en) | 2018-10-26 | 2024-12-31 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Pyrimidopyrazolone derivative as Wee1 inhibitor and use thereof |
-
2020
- 2020-04-30 SI SI202030468T patent/SI3964510T1/sl unknown
- 2020-04-30 US US17/607,447 patent/US12291536B2/en active Active
- 2020-04-30 WO PCT/CN2020/088451 patent/WO2020221358A1/zh not_active Ceased
- 2020-04-30 AU AU2020266956A patent/AU2020266956B2/en active Active
- 2020-04-30 HR HRP20241008TT patent/HRP20241008T1/hr unknown
- 2020-04-30 CN CN202080031816.4A patent/CN113784968B/zh active Active
- 2020-04-30 PT PT207989245T patent/PT3964510T/pt unknown
- 2020-04-30 EP EP20798924.5A patent/EP3964510B1/en active Active
- 2020-04-30 PL PL20798924.5T patent/PL3964510T3/pl unknown
- 2020-04-30 SM SM20240303T patent/SMT202400303T1/it unknown
- 2020-04-30 FI FIEP20798924.5T patent/FI3964510T3/fi active
- 2020-04-30 ES ES20798924T patent/ES2984617T3/es active Active
- 2020-04-30 JP JP2021564588A patent/JP7582970B2/ja active Active
- 2020-04-30 DK DK20798924.5T patent/DK3964510T3/da active
- 2020-04-30 BR BR112021021230A patent/BR112021021230A8/pt unknown
- 2020-04-30 CA CA3138240A patent/CA3138240C/en active Active
- 2020-04-30 HU HUE20798924A patent/HUE068061T2/hu unknown
- 2020-04-30 LT LTEPPCT/CN2020/088451T patent/LT3964510T/lt unknown
- 2020-04-30 SG SG11202111315XA patent/SG11202111315XA/en unknown
- 2020-04-30 RS RS20240816A patent/RS65747B1/sr unknown
-
2021
- 2021-10-21 IL IL287472A patent/IL287472A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2984617T3 (es) | 2024-10-30 |
| SG11202111315XA (en) | 2021-11-29 |
| BR112021021230A2 (https=) | 2021-12-21 |
| RS65747B1 (sr) | 2024-08-30 |
| US12291536B2 (en) | 2025-05-06 |
| SI3964510T1 (sl) | 2024-10-30 |
| BR112021021230A8 (pt) | 2023-04-25 |
| IL287472A (en) | 2021-12-01 |
| PT3964510T (pt) | 2024-07-29 |
| AU2020266956B2 (en) | 2025-05-08 |
| CN113784968A (zh) | 2021-12-10 |
| PL3964510T3 (pl) | 2024-08-19 |
| CN113784968B (zh) | 2024-03-15 |
| HRP20241008T1 (hr) | 2024-11-08 |
| JP2022530812A (ja) | 2022-07-01 |
| HUE068061T2 (hu) | 2024-12-28 |
| SMT202400303T1 (it) | 2024-09-16 |
| EP3964510A1 (en) | 2022-03-09 |
| FI3964510T3 (fi) | 2024-07-24 |
| EP3964510B1 (en) | 2024-07-03 |
| EP3964510A4 (en) | 2023-04-26 |
| JP7582970B2 (ja) | 2024-11-13 |
| US20220220120A1 (en) | 2022-07-14 |
| AU2020266956A1 (en) | 2021-10-28 |
| DK3964510T3 (da) | 2024-07-29 |
| CA3138240A1 (en) | 2020-11-05 |
| WO2020221358A1 (zh) | 2020-11-05 |
| LT3964510T (lt) | 2024-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3138240C (en) | CRYSTALLINE FORMS OF A WEE1 INHIBITING COMPOUND AND RELATED USES | |
| US12479839B2 (en) | Crystalline form of ATR inhibitor and use thereof | |
| CN110872277B (zh) | N-取代芳环-2-氨基嘧啶类化合物及用途 | |
| CN111253370B (zh) | N-多取代吡啶-2-氨基嘧啶类衍生物及用途 | |
| CN115448874B (zh) | 固体形式的周期蛋白依赖性激酶9抑制剂及其用途 | |
| RU2842334C2 (ru) | Кристаллическая форма ингибирующего wee1 соединения и ее применение | |
| KR20250154490A (ko) | 방향족 아미드 유도체, 이의 제조 방법, 및 그의 용도 | |
| RU2832707C2 (ru) | Кристаллическая форма ингибитора atr и ее применение | |
| JP7762460B2 (ja) | １Ｈ－ピロロ［２，３－ｃ］ピリジン系化合物の結晶形及びその製造方法 | |
| WO2020224585A1 (zh) | 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 | |
| EP4467536A1 (en) | Crystalline form of sulfur-containing isoindoline derivative | |
| HK40060045B (zh) | Wee1抑制剂化合物的晶型及其应用 | |
| HK40060045A (en) | Crystal form of wee1 inhibitor compound and use thereof | |
| CN116768826B (zh) | 一种含氮杂环的一枝蒿酮酸酰胺衍生物及其制备方法和用途 | |
| RU2783243C2 (ru) | Макроциклическое соединение, выполняющее функции ингибитора wee1, и варианты его применения | |
| CN121487955A (zh) | 一种含丙烯酮类生物抑制剂的晶型及其制备方法和应用 | |
| EP4653445A1 (en) | Cdk inhibitor and crystal form of pharmaceutically acceptable salt thereof, and use thereof | |
| EA049096B1 (ru) | Кристаллическая форма фторзамещенного соединения пиридопиразола и способ ее получения | |
| HK40074313B (zh) | 一种atr抑制剂的晶型及其应用 | |
| BR112020008664B1 (pt) | Composto macrocíclico que atua como inibidor de wee1 e aplicações do mesmo | |
| HK40039872A (en) | Angiotensin ii receptor 2 antagonist salt form and crystalline form, and preparation method therefor | |
| WO2019085927A1 (zh) | Fgfr4抑制剂的盐、晶体、制备方法及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220720 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20250310 |
|
| Q17 | Modified document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED Effective date: 20250327 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE Effective date: 20250401 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250414 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250414 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250502 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260325 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260326 |